| 2009 | A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status | ONCOLOGY |
| 2010 | A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
| 2006 | A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer | ONCOLOGY |
| 2008 | A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2007 | A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
| BRITISH JOURNAL OF CANCER |
| 2007 | A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2011 | A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
| CANCER |
| 2015 | A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2004 | Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2011 | Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis.
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 1998 | Alpha-fetoprotein-producing gastric cancer | ONCOLOGY REPORTS |
| 2012 | Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
| BMC CANCER |
| 2007 | Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: A 15-year follow-up study at a single korean institute | ANNALS OF SURGICAL ONCOLOGY |
| 2013 | Changing treatment patterns in elderly patients with resectable colon cancer | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
| 2010 | Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression | CANCER SCIENCE |
| 2008 | Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients
| BMC CANCER |
| 2010 | Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients | CANCER LETTERS |
| 1997 | Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate | CANCER LETTERS |
| 2009 | Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer | INTERNATIONAL JOURNAL OF ONCOLOGY |
| 2001 | Early Postoperative Intraperitoneal Chemotherapy with Mitomycin C, 5-Fluorouracil and Cisplatin for Advanced Gastric Cancer | ONCOLOGY |
| 2011 | Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis | ONCOLOGY |
| 2001 | Efficacy of Pre - and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
| CANCER RESEARCH AND TREATMENT |
| 2013 | Estimating the Adjuvant Chemotherapy Effect in Elderly Stage II and III Colon Cancer Patients in an Observational Study | JOURNAL OF SURGICAL ONCOLOGY |
| 2011 | Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. | ONCOLOGY REPORTS |
| 1997 | High Level of Urokinase-Type Plasminogen Activator Is a New Prognostic Marker in Patients with Gastric Carcinoma | CANCER |
| 2012 | Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer | SURGICAL ONCOLOGY-OXFORD |
| 2015 | Leiomyosarcoma: investigation of prognostic factors for risk-stratification model | INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY |
| 2006 | Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports
| CANCER RESEARCH AND TREATMENT |
| 2008 | Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer | CANCER LETTERS |
| 1999 | Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer | International Journal of Molecular Medicine |
| 2015 | Novel methods for clinical risk stratification in patients with colorectal liver metastases
| CANCER RESEARCH AND TREATMENT |
| 2006 | Oncologic Outcomes After Neoadjuvant Chemoradiation Followed by Curative Resection With Tumor-Specific Mesorectal Excision for Fixed Locally Advanced Rectal Cancer: Impact of Postirradiated Pathologic Downstaging on Local Recurrence and Survival | ANNALS OF SURGERY |
| 2010 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2016 | p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
| CANCER RESEARCH AND TREATMENT |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 2008 | Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
| ANNALS OF ONCOLOGY |
| 2010 | Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 2008 | Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
| ANNALS OF ONCOLOGY |
| 2009 | Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2011 | Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer | ANTI-CANCER DRUGS |
| 2009 | Prognostic factors affecting oncologic outcomes in patients with locally recurrent rectal cancer: impact of patterns of pelvic recurrence on curative resection | LANGENBECKS ARCHIVES OF SURGERY |
| 2013 | Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study | ANNALS OF SURGICAL ONCOLOGY |
| 1997 | Relationship between p53 Overexpression and Gastric Cancer Progression | ONCOLOGY |
| 1997 | Retrospective Comparison of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Modified FAM) Combination Chemotherapy Versus Palliative Therapy in Treatment of Advanced Gastric Cancer | American Journal of Clinical Oncology |
| 2011 | Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
| CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2002 | Suppression of peritoneal metastasis by expression of murine endostatin cDNA
| CANCER RESEARCH AND TREATMENT |
| 2008 | Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases
| ANNALS OF ONCOLOGY |
| 1998 | Telomerase Activity and Telomere Lengths in Various Cell Lines: Changes of Telomerase Activity Can Be Another Method for Chemosensitivity Evaluation | INTERNATIONAL JOURNAL OF ONCOLOGY |
| 2010 | Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 1997 | 근치적 위절제술을 시행받은 위암 환자에서 상황(메시마-엑스)의 항종양 효과
| Journal of the Korean Cancer Association (대한암학회지) |
| 2002 | 동소이식을 이용한 위암의 전이모델.
| JOURNAL OF THE KOREAN SURGICAL SOCIETY |
| 1997 | 생물학적 치료 목표로서 위암에서 Midkine 발현의 탐색 | Journal of the Korean Cancer Association (대한암학회지) |
| 1997 | 위암 진행 표지자로서 혈액내 Intercellular Adhesion Molecule-1 (ICAM-1)과 Vascular Cell Adhesion Molecule-1 (VCAM-1)의 동시 발현 | Journal of the Korean Cancer Association (대한암학회지) |
| 1997 | 위암 환자의 혈액 및 조직에서 Urokinase-type Plasminogen Activator 발현의 임상적 의의 | Journal of the Korean Cancer Association (대한암학회지) |
| 1996 | 위암에서 Collagen-4 및 Type-4 Collagenase의 발현과 예후인자로서 임상적 응용
| Korean Journal of Gastroenterology |
| 1996 | 위암에서 침윤과 전이의 새로운 생물학적 표지자로서 urokinase-type plasminogen activator(uPA)의 발현
| Journal of the Korean Cancer Association(대한암학회지) |
| 1995 | 위암환자의 종양지표지자로서 혈액내 c-erbB-2 종양단백의 탐색
| Journal of the Korean Cancer Association(대한암학회지) |
| 1995 | 인체 위암조직에서 새로운 생물학적 치료목표로서 기저막 단백분해효소(Matrix-metalloproteinase-2,-9)의 발현
| Journal of the Korean Cancer Association(대한암학회지) |
| 2008 | 절제 불가능한 결장직장암의 원격전이 환자에서 표적치료제를 포함한 선행항암화학요법 후 시행한 근치적인 절제술
| Journal of the Korean Society of Coloproctology |
